This drug from the thiazolidinedione class is now approved for use incombination therapy with insulin, expanding on the existing indicationsas monotherapy and as combination therapy with metformin or sulfonylureas.Rosiglitazone improves sensitivity to insulin in muscle and adipose tissueand inhibits hepatic gluconeogenesis.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Avandia (rosiglitazone)

Newsletter